Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Bladder cancer chemotherapy neoadjuvant therapy

Asian People/genetics Biomarkers Tumor/*blood/urine Cystoscopy/adverse effects Humans MicroRNAs/*blood Neoplasm Staging Nuclear Proteins/urine Odds Ratio ROC Curve Regression Analysis Sensitivity and Specificity Urinalysis/methods Urinary Bladder Neoplasms/*blood/diagnosis/*genetics/urine Bladder cancer Diagnosis Meta-analysis miRNA authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cystectomy/*adverse effects Diurnal Enuresis/etiology Female Humans Nocturnal Enuresis/etiology *Quality of Life Sexual Dysfunction Physiological/*etiology/physiopathology Urinary Bladder Neoplasms/*surgery Urinary Diversion/adverse effects Urinary Incontinence/*etiology Cystectomy Functional outcomes Gender disparities Outcomes assessment Urinary bladder neoplasms

*Adaptation Psychological Humans Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/mortality/pathology/*psychology Bladder cancer Cystectomy Diagnosis Patients’ experience Treatment FUNDING: This work was funded by Yorkshire Cancer Research (grant number S388).

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Adult Aged Aged 80 and over Humans Magnetic Resonance Imaging/standards Middle Aged Muscle Neoplasms/*diagnosis Neoplasm Invasiveness Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis Bladder cancer Local staging Magnetic resonance imaging Meta-analysis Muscle-invasive bladder cancer Systematic review

Arylamine N-Acetyltransferase/*genetics Genetic Predisposition to Disease Humans Isoenzymes/genetics Polymorphism Genetic Urinary Bladder Neoplasms/*genetics

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Diabetes Mellitus/diagnosis/*drug therapy/epidemiology Dose-Response Relationship Drug Humans Hypoglycemic Agents/*adverse effects Linear Models Multivariate Analysis Odds Ratio Pioglitazone Risk Assessment Risk Factors Thiazolidinediones/*adverse effects Time Factors Urinary Bladder Neoplasms/*chemically induced/diagnosis/epidemiology

Humans *Lymph Node Excision Lymphatic Metastasis Muscle Smooth/pathology Neoplasm Invasiveness Prognosis Urinary Bladder Neoplasms/pathology/*surgery Cáncer vesical con infiltración de la muscular Linfadenectomía Lymph node anatomical territory Lymphadenectomy Muscle invasive bladder cancer Oncological value Territorios anatómicos ganglionares Valor oncológico

Ki-67 bladder cancer meta-analysis prognosis urothelial carcinoma

PSCA 膀胱癌 基因多态性 Meta分析

Biomarkers Tumor/*urine Carcinoma Transitional Cell/pathology/*urine Gene Expression Regulation Neoplastic Humans Prognosis RNA Long Noncoding/*urine Urinary Bladder Neoplasms/pathology/*urine Bladder cancer biomarker diagnosis long non-coding RNA urothelial carcinoma–associated 1

Antioxidants/*therapeutic use Databases Factual Dietary Supplements Humans Randomized Controlled Trials as Topic Risk Urinary Bladder Neoplasms/pathology/*prevention & control Vitamins/*therapeutic use beta Carotene/therapeutic use Antioxidant Bladder Cancer Meta-Analysis Randomized Controlled Trials Vitamin

Cystectomy/*methods Disease-Free Survival Humans Lymphatic Metastasis *Margins of Excision Neoplasm Recurrence Local Neoplasm Staging Prognosis Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery bladder cancer meta-analysis outcome radical cystectomy surgical margin status

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Bladder cancer biomarker protein urine